Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHA-794428 single-dose crossover study in adult male growth hormone deficiency
2005-001658-25Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2005
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of PHA-794428 in adult onset growth hormone deficiency (AGHD) (2 arms), sponsored by Pfizer. Primary endpoints: Safety and tolerance of a single subcutaneous injection of PHA-794428, Pharmacodynamic effects on IGF-1 and 1 more. Started Jul 2005; status: completed.
02
Drugs
PHA-794428
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on 2005-001658-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001658-25.